Skip to main content

Table 2 Baseline demographics and clinical characteristics

From: Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial

  Arm A* Arm B
Auxora (n = 17) SOC (n = 9) Auxora (n = 3) SOC (n = 1)
Age, years (mean ± SD) 59 ± 12 61 ± 13 64 ± 14 36 ± NA
Median BMI, kg/m2 (min, max) 30 (25, 79) 30 (23, 49) 23 (18, 36) 34
Male sex, n (%) 7 (41) 5 (56) 1 (33) 1 (100)
Ethnicity, n (%)
 White 8 (47) 5 (56) 1 (33) 0
 Black or African American 7 (41) 3 (33) 1 (33) 1 (100)
 Asian 0 1 (11) 1 (33) 0
 Others/multiple 2 (12) 0 0 0
Hispanic or Latino, n (%) 2 (12) 1 (11) 0 0
Diabetes, n (%) 8 (47) 2 (22) 2 (67) 0 (0)
Hypertension, n (%) 8 (47) 4 (44) 2 (67) 0 (0)
Median time from the onset of symptoms to randomization, days (min, max) 9 (4, 34) 7 (4, 11) 11 (8, 17) 13
Ferritin, ng/mL (mean ± SD) 709 ± 553 772 ± 742 1776 ± 722 2151 ± NA
CRP, mg/dL (mean ± SD) 10 ± 7 12 ± 6 14 ± 11 9 ± NA
PaO2/FiO2 (mean ± SD) 178 ± 74 168 ± 78 106 ± 45 87 ± NA
 PaO2/FiO2 ≥ 201 7 (41) 3 (33) 0 0
 PaO2/FiO2 101–200 6 (35) 4 (44) 2 (67) 0
 PaO2/FiO2 ≤ 100 4 (24) 2 (22) 1 (33) 1 (100)
PaO2/FiO2 101–200 ferritin ng/mL (mean ± SD) 867 ± 712 910 ± 1090 1637 ± 963 NA
PaO2/FiO2 101–200 CRP mg/dL (mean ± SD) 11 ± 5 13 ± 9 16 ± 15 NA
  1. Baseline demographics were balanced across the Auxora and standard of care groups in arm A. In arm B, baseline characteristics were more variable due to the small sample size
  2. NA not available, SOC standard of care
  3. *Patients in arm A included those who were receiving low-flow supplemental oxygen at screening and were defined by regulatory guidance as having severe COVID-19 pneumonia
  4. Patients in arm B were defined by regulatory guidelines as having critical COVID-19 pneumonia
\